DV
Dividend Vision

COYA — Coya Therapeutics, Inc. Common Stock

Coya Therapeutics, Inc. Common Stock (COYA)

Total return is 4.8% over the past 3.6 years, 106.9 points behind SPY at 111.7%. Its deepest 1-year drawdown was 48.6%.

This appears to be a single stock listing rather than a diversified ETF product. Coya Therapeutics is a therapeutic development company whose shares trade on the market, but it does not function as a traditional ETF with a defined investment strategy, portfolio of underlying assets, or stated objective. With no distribution rate, expense ratio, or assets under management data available, this holding offers no yield profile or regular income distributions, making it unsuitable for income-focused dividend investors; instead, it represents a direct equity position in a single biotech company appropriate only for those with specific knowledge of and conviction in the company's pipeline and prospects.

COYA key facts

Asset type
Stock
Asset class
Equity
Inception date
12/29/2022
Last close
$4.79
Market cap
$106,495,616
Average volume
113556.0
Beta
0.513
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.15